Glucocorticoid_NN
receptor_NN
characteristics_NNS
in_IN
monocytes_NNS
of_IN
patients_NNS
with_IN
corticosteroid-resistant_JJ
bronchial_JJ
asthma_NN
._.

The_DT
mechanism_NN
of_IN
corticosteroid_NN
resistance_NN
in_IN
bronchial_JJ
asthma_NN
has_VBZ
been_VBN
studied_VBN
by_IN
determining_VBG
the_DT
rank_NN
order_NN
of_IN
potency_NN
for_IN
different_JJ
corticosteroids_NNS
in_IN
inhibiting_VBG
the_DT
generation_NN
of_IN
a_DT
3_CD
kD_NN
molecule_NN
from_IN
peripheral_JJ
blood_NN
monocytes_NNS
isolated_VBN
from_IN
corticosteroid-sensitive_JJ
-LRB-_-LRB-
CS_NN
-RRB-_-RRB-
and_CC
corticosteroid-resistant_JJ
-LRB-_-LRB-
CR_NN
-RRB-_-RRB-
asthmatic_JJ
subjects_NNS
,_,
which_WDT
augments_VBZ
leukotriene_NN
B4_NN
-LRB-_-LRB-
LTB4_NN
-RRB-_-RRB-
generation_NN
by_IN
human_JJ
neutrophils_NNS
-LRB-_-LRB-
PMN_NN
-RRB-_-RRB-
stimulated_VBN
by_IN
calcium_NN
ionophore_NN
._.

In_IN
addition_NN
,_,
binding_VBG
studies_NNS
with_IN
-LRB-_-LRB-
3H_NN
-RRB-_-RRB-
dexamethasone_NN
have_VBP
been_VBN
performed_VBN
to_TO
determine_VB
the_DT
dissociation_NN
constant_NN
-LRB-_-LRB-
Kd_NN
-RRB-_-RRB-
and_CC
receptor_NN
numbers_NNS
-LRB-_-LRB-
Ro_NN
-RRB-_-RRB-
in_IN
the_DT
monocytes_NNS
of_IN
these_DT
two_CD
groups_NNS
of_IN
subjects_NNS
._.

The_DT
concentration_NN
of_IN
corticosteroid_NN
producing_VBG
50_CD
%_NN
inhibition_NN
-LRB-_-LRB-
IC50_NN
-RRB-_-RRB-
was_VBD
600_CD
nM_NN
,_,
70_CD
nM_NN
,_,
and_CC
0.5_CD
nM_NN
for_IN
hydrocortisone_NN
,_,
methylprednisolone_NN
,_,
and_CC
dexamethasone_NN
,_,
respectively_RB
,_,
in_IN
monocytes_NNS
from_IN
CS_JJ
individuals_NNS
._.

There_EX
was_VBD
only_RB
weak_JJ
inhibition_NN
of_IN
the_DT
generation_NN
of_IN
enhancing_VBG
activity_NN
by_IN
the_DT
corticosteroids_NNS
in_IN
the_DT
CR_JJ
asthmatic_JJ
individuals_NNS
._.

The_DT
dexamethasone_NN
Kd_NN
was_VBD
2.45_CD
+_CC
\/_JJ
-_:
0.58_CD
nM_NN
-LRB-_-LRB-
mean_CD
+_CC
\/_NN
-_:
SEM_NN
,_,
n_NN
=_JJ
6_CD
-RRB-_-RRB-
in_IN
the_DT
CS_JJ
group_NN
and_CC
1.6_CD
+_CC
\/_CD
-_:
0.35_CD
nM_NN
-LRB-_-LRB-
mean_CD
+_CC
\/_NN
-_:
SEM_NN
,_,
n_NN
=_JJ
6_CD
-RRB-_-RRB-
in_IN
the_DT
CR_JJ
group_NN
of_IN
patients_NNS
-LRB-_-LRB-
p_NN
=_JJ
0.14_CD
-RRB-_-RRB-
._.

The_DT
Ro_NN
in_IN
the_DT
CS_JJ
group_NN
was_VBD
3,605_VBN
+_CC
\/_NN
-_:
984_CD
binding_VBG
sites_NNS
per_IN
nucleus_NN
-LRB-_-LRB-
mean_CD
+_CC
\/_NN
-_:
SEM_NN
,_,
n_NN
=_JJ
6_CD
-RRB-_-RRB-
and_CC
4,757_CD
+_CC
\/_CD
-_:
692_CD
binding_VBG
sites_NNS
per_IN
nucleus_NN
-LRB-_-LRB-
mean_CD
+_CC
\/_NN
-_:
SEM_NN
,_,
n_NN
=_JJ
6_CD
-RRB-_-RRB-
in_IN
the_DT
CR_NN
group_NN
-LRB-_-LRB-
p_NN
=_JJ
0.23_CD
-RRB-_-RRB-
._.

These_DT
findings_NNS
indicate_VBP
that_IN
corticosteroid_NN
resistance_NN
in_IN
bronchial_JJ
asthma_NN
can_MD
not_RB
be_VB
explained_VBN
by_IN
abnormalities_NNS
in_IN
corticosteroid_NN
receptor_NN
characteristics_NNS
._.

